{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:15:45Z","timestamp":1781842545850,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.pupt.2013.09.003","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T04:19:12Z","timestamp":1380082752000},"page":"171-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effectiveness and safety of macrolides in bronchiectasis patients: A meta-analysis and systematic review"],"prefix":"10.1016","volume":"28","author":[{"given":"Zu-Liang","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Gui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2013.09.003_bib1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMra012519","article-title":"Bronchiectasis","volume":"346","author":"Barker","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"48","key":"10.1016\/j.pupt.2013.09.003_bib2","first-page":"809","article-title":"Bronchiectasis\u2014diagnosis and treatment","volume":"108","author":"Rademacher","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.pupt.2013.09.003_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00069007","article-title":"Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms","volume":"31","author":"Fuschillo","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2013.09.003_bib4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Martinez-Garcia","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2013.09.003_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1164\/ajrccm.156.2.9607083","article-title":"Validation of the St. George's Respiratory Questionnaire in bronchiectasis","volume":"156","author":"Wilson","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2013.09.003_bib6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1183\/09031936.00003709","article-title":"Mortality in bronchiectasis: a long-term study assessing the factors influencing survival","volume":"34","author":"Loebinger","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2013.09.003_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.rmed.2010.02.022","article-title":"Trends in bronchiectasis mortality in England and Wales","volume":"104","author":"Roberts","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2013.09.003_bib8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2013.09.003_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.pupt.2013.09.003_bib10","series-title":"Meta-analysis, decision analysis, and cost-effectiveness analysis","author":"Petitti","year":"1994"},{"key":"10.1016\/j.pupt.2013.09.003_bib11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.pupt.2013.09.003_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.pupt.2013.09.003_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2431-12-122","article-title":"Azithromycin for indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial","volume":"12","author":"Valery","year":"2012","journal-title":"BMC Pediatr"},{"issue":"6","key":"10.1016\/j.pupt.2013.09.003_bib14","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.rmed.2011.01.009","article-title":"Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations","volume":"105","author":"Serisier","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2013.09.003_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1183\/09031936.97.10050994","article-title":"Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study","volume":"10","author":"Koh","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2013.09.003_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/09031936.99.13236199","article-title":"A\u00a0pilot study of low-dose erythromycin in bronchiectasis","volume":"13","author":"Tsang","year":"1999","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.pupt.2013.09.003_bib17","first-page":"117","article-title":"The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis treat","volume":"4","author":"Cymbala","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2013.09.003_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomized, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pupt.2013.09.003_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis","volume":"309","author":"Altenburg","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"issue":"12","key":"10.1016\/j.pupt.2013.09.003_bib20","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis","volume":"309","author":"Serisier","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.pupt.2013.09.003_bib21","unstructured":"De Diego A, Milara J, Martinez E. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. 10.1111\/resp.12130."},{"issue":"11","key":"10.1016\/j.pupt.2013.09.003_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002203.pub4","article-title":"Macrolide antibiotics for cystic fibrosis","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.pupt.2013.09.003_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007716.pub3","article-title":"Macrolides for diffuse panbronchiolitis","author":"Yang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pupt.2013.09.003_bib24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pharmthera.2007.11.001","article-title":"Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action","volume":"117","author":"Shinkai","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pupt.2013.09.003_bib25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1469-0691.2010.03317.x","article-title":"Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients","volume":"17","author":"Garcia-Castillo","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pupt.2013.09.003_bib26","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1128\/AAC.00372-10","article-title":"Efficacy of the combination of tobramycin and a macrolide in an in\u00a0vitro Pseudomonas aeruginosa mature biofilm model","volume":"54","author":"Tre-Hardy","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2013.09.003_bib27","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1128\/AAC.00102-10","article-title":"Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"54","author":"Elliott","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2013.09.003_bib28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dkr040","article-title":"Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review","volume":"66","author":"Cai","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2013.09.003_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1378\/chest.07-1631","article-title":"Airway inflammation in cystic fibrosis","volume":"133","author":"Elizur","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2013.09.003_bib30","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"issue":"10","key":"10.1016\/j.pupt.2013.09.003_bib31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2013.09.003_bib32","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.pupt.2013.09.003_bib33","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.pupt.2013.09.003_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.pupt.2013.09.003_bib35","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa","volume":"303","author":"Saiman","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"issue":"4","key":"10.1016\/j.pupt.2013.09.003_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijantimicag.2009.05.008","article-title":"Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005","volume":"34","author":"Karlowsky","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.pupt.2013.09.003_bib37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3201\/eid1106.050198","article-title":"Community prescribing and resistant Streptococcus pneumoniae","volume":"11","author":"Barkai","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.pupt.2013.09.003_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jac\/48.2.225","article-title":"High proportion of pharyngeal carriers of commensal streptococci resistant to erythromycin in Spanish adults","volume":"48","author":"Perez-Trallero","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl.\u00a0S2","key":"10.1016\/j.pupt.2013.09.003_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/dkf512","article-title":"Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides","volume":"50","author":"Lonks","year":"2002","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2013.09.003_bib40","doi-asserted-by":"crossref","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews","volume":"338","author":"Song","year":"2009","journal-title":"BMJ"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553913001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553913001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T09:49:10Z","timestamp":1564048150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553913001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1094553913001727"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2013.09.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of macrolides in bronchiectasis patients: A meta-analysis and systematic review","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2013.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}